Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Mitnick, Carole D ^a,b   Rodriguez, Carly A ^a   Hatton, Marita L ^c   Brigden, Grania ^d   Cobelens, Frank ^e   Grobusch, Martin P ^f   Horsburgh, Robert ^c   Lange, Christoph ^g,h,i   Lienhardt, Christian ^j   Oren, Eyal ^k   Podewils, Laura J ^l   Seaworth, Barbara ^m   Van Hof, Susan Den ^e   Daley, Charles L ⁿ   Gebhard, Agnes C ^e   Wares, Fraser ^j  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PARTNERS IN HEALTH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g RESEARCH CENTER BORSTEL   (Germany)

^h UNIVERSITY OF NAMIBIA   (Namibia)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j WORLD HEALTH ORGANIZATION   (Switzerland)

^k UNIVERSITY OF ARIZONA   (United States)

^l CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^m Heartland National TB Center   (United States)

ⁿ UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; MOXIFLOXACIN; PYRAZINAMIDE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL TRANSMISSION; DIAGNOSTIC TEST; DRUG RESISTANT TUBERCULOSIS; EPIDEMIC; EXTRAPULMONARY TUBERCULOSIS; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LATENT TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; POST EXPOSURE PROPHYLAXIS; RESEARCH PRIORITY; TREATMENT DURATION; FEMALE; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

FEMALE; HUMANS; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84971237998     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155968     Document Type: Article

References (48)

1. Global tuberculosis report 2015. Geneva: World Health Organization; 2015 (WHO/HTM/TB/2015.22).
2. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: World Health Organization; 2008 (WHO/HTM/TB/2008.402).
3. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.6).
4. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014. (WHO/HTM/TB/2014.11).
5. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.361).
6. Global tuberculosis report 2013. Geneva: World Health Organization; 2013 (WHO/HTM/TB/2013.11)
7. Global tuberculosis report 2014. Geneva: World Health Organization; 2014 (WHO/HTM/TB/2014.08).
8. Gupta R, Espinal M. A prioritised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis. 2003; 7(5):410-4. PMID: 12757039
9. Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med. 2008; 5(7):e150. doi: 10.1371/journal.pmed.0050150 PMID: 18613746
10. Lessells RJ, Cooke GS, Newell ML, Godfrey-Faussett P. Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact. J Infect Dis. 2011; 204 Suppl 4:S1187-95. doi: 10.1093/infdis/jir412 PMID: 21996701
11. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 377(9760):147-52. doi: 10.1016/S0140-6736(10)61972-1 PMID: 21145581
12. Cobelens F, van Kampen S, Ochodo E, Atun R, Lienhardt C. Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review. PLoS Med. 2012; 9(12):e1001358. doi: 10.1371/journal.pmed.1001358 PMID: 23271959
13. Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet. 375(9732):2179-91. doi: 10.1016/S0140-6736(10)60554-5 PMID: 20488521
14. Mitnick CD, Keravec J, Cohen T. Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TB. Int J Tuberc Lung Dis. 2013; 17(4):427-8. doi: 10.5588/ijtld.13.0110 PMID: 23485374
15. Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, Diagnosis, and Treatment of Tuberculosis in Children and Mothers: Evidence for Action for Maternal, Neonatal, and Child Health Services. J Infect Dis. 2012.
16. Chiang C-Y, Centis R, Migliori GB. Drug-resistant tuberculosis: Past, present, future. Respirology. 2010; 15(3):413-32. doi: 10.1111/j.1440-1843.2010.01738.x PMID: 20337989
17. Gammino VM, Taylor AB, Rich ML, Bayona J, Becerra MC, Bonilla C, et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis. 2011; 15(10):1315-22. doi: 10.5588/ijtld.10.0221 PMID: 22283887
18. Horsburgh CR, Shea KM, Phillips P, Lavalley M. Randomized clinical trials to identify optimal antibiotic treatment duration. Trials. 2013; 14:88. doi: 10.1186/1745-6215-14-88 PMID: 23536969
19. Lienhardt C, Davies G. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities. Int J Tuberc Lung Dis. 2010; 14(5):528-37. PMID: 20392344
20. Becerra MC, Franke MF, Appleton SC, Joseph JK, Bayona J, Atwood SS, et al. Tuberculosis in Children Exposed at Home to Multidrug-resistant Tuberculosis. Pediatr Infect Dis J. 2013; 32(2):115-9. doi: 10.1097/INF.0b013e31826f6063 PMID: 22926210
21. Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis. 2012; 12(6):469-79. doi: 10.1016/S1473-3099(11)70366-8 PMID: 22373591
22. van der Werf MJ, Langendam MW, Sandgren A, Manissero D. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis. 2012; 16(3):288-96. doi: 10.5588/ijtld.11.0437 PMID: 22640442
23. Rylance J, Pai M, Lienhardt C, Garner P. Priorities for tuberculosis research: a systematic review. Lancet Infect Dis. 2010; 10(12):886-92. doi: 10.1016/S1473-3099(10)70201-2 PMID: 21050822
24. Grange J, Mwaba P, Dheda K, Höelscher M, Zumla A. World TB Day 2010 -New innovations are required for enhancing the global fight against Tuberculosis: the 'Captain of all these men of death'. Trop Med Int Health. 2010; 15(3):274-6. doi: 10.1111/j.1365-3156.2009.02462.x PMID: 20070628
25. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182(5):684-92. doi: 10.1164/rccm.201001-0077OC PMID: 20442432
26. Nunn AJ, Rusen I, Van Deun A, Torrea G, Phillips PP, Chiang CY, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014; 15(1):353.
27. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014; 18(10):1180-7. doi: 10.5588/ijtld.14.0100 PMID: 25216831
28. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014; 371(8):723-32. doi: 10. 1056/NEJMoa1313865 PMID: 25140958
29. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013; 41(6):1393-400. doi: 10.1183/09031936.00125812 PMID: 23018916
30. Médecins Sans Frontières. endTB, Expand New Drug Markets for TB 2014 [November 6, 2015]. Available from: http://www.msf.org/sites/msf.org/files/1503-endtb-presdoc-new.pdf.
31. Partners in Health. PIH among Groups Bringing New TB Treatment to Those in Need 2015 [November 6, 2015]. Available from: http://www.pih.org/press/pih-among-organizations-bringing-new-tb-treatmentto-those-in-need.
32. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365(23):2155-66. doi: 10.1056/NEJMoa1104875 PMID: 22150035
33. Seddon JA, Hesseling AC, Finlayson H, Fielding K, Cox H, Hughes J, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis. 2013; 57 (12):1676-84. doi: 10.1093/cid/cit655 PMID: 24065321
34. Thee S, Garcia-Prats AJ, McIlleron HM, Wiesner L, Castel S, Norman J, et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. Antimicrob Agents Chemother. 2014; 58(5):2948-51. doi: 10.1128/AAC.02755-13 PMID: 24550337
35. Adler-Shohet FC, Low J, Carson M, Girma H, Singh J. Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2014; 33(6):664-6. doi: 10.1097/ INF.0000000000000260 PMID: 24445837
36. Bamrah S, Brostrom R, Dorina F, Setik L, Song R, Kawamura LM, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis. 2014; 18 (8):912-8. doi: 10.5588/ijtld.13.0028 PMID: 25199004
37. Williams B, Ramroop S, Shah P, Anderson L, Das S, Riddell A, et al. Management of pediatric contacts of multidrug resistant tuberculosis in the United Kingdom. Pediatr Infect Dis J. 2013; 32(8):926-7.
38. Clayden P, Collins S, Frick M, Harrington M, Horn T, Jefferys R, et al. 2015 Pipeline Report: HIV, hepatitis C visus (HCV), and tuberculosis (TB). Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development New York, NY: HIV i-Base/Treatment Action Group; 2015 [November 6, 2015]. Available from: http://i-base.info/htb/28492.
39. Network I. IMPAACT 2003B: (PHOENIx) (DAIDS ID 12041): Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients 2015 [cited 2015 December 14]. Available from: http://impaactnetwork.org/studies/IMPAACT2003B.asp.
40. Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, et al. Time to Treatment and Patient Outcomes among TB Suspects Screened by a Single Point-of-Care Xpert MTB/RIF at a Primary Care Clinic in Johannesburg, South Africa. PLoS ONE. 2013; 8(6):e65421. doi: 10.1371/journal. pone.0065421 PMID: 23762367
41. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, Wood R. Characteristics and Early Outcomes of Patients With Xpert MTB/RIF-Negative Pulmonary Tuberculosis Diagnosed During Screening Before Antiretroviral Therapy. Clin Infect Dis. 2012; 54(8):1071-9. doi: 10.1093/cid/cir1039 PMID: 22318975
42. Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, et al. Impact of Xpert MTB/ RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial. Open Forum Infect Dis. 2014; 1(1):ofu038. doi: 10.1093/ofid/ofu038 PMID: 25734106
43. Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Cobelens F, et al. Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial. PLoS ONE. 2015; 10(4):e0123252. doi: 10. 1371/journal.pone.0123252 PMID: 25915745
44. Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, Kalema N, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One. 2012; 7(11):e48599. doi: 10.1371/journal.pone.0048599 PMID: 23139799
45. Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a steppedwedge cluster-randomized trial. PLoS Med. 2014; 11(12):e1001766. doi: 10.1371/journal.pmed.1001766 PMID: 25490549
46. Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J. 2013; 42(3):701-7. doi: 10.1183/09031936. 00175812 PMID: 23222872
47. Frick M. Tuberculosis Research and Development: 2014 Report on Tuberculosis Research Funding Trends, 2005-2013. Treatment Action Group Stop TB Partnership, 2014.
48. Médecins Sans Frontières. The 3P Project: A new approach to developing better treatments for TB 2015 [November 6, 2015]. Available from: http://www.msfaccess.org/spotlight-on/3p-project-newapproach-developing-better-treatments-tb.